The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness.

Syed Muhammad Zubair, Muhammad Waleed Chaudhry, Ali Bin Sarwar Zubairi, Talha Shahzad, Aqusa Zahid, Ibrahim Ali Khan, Javaid Ahmed Khan, Muhammad Irfan
{"title":"The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness.","authors":"Syed Muhammad Zubair,&nbsp;Muhammad Waleed Chaudhry,&nbsp;Ali Bin Sarwar Zubairi,&nbsp;Talha Shahzad,&nbsp;Aqusa Zahid,&nbsp;Ibrahim Ali Khan,&nbsp;Javaid Ahmed Khan,&nbsp;Muhammad Irfan","doi":"10.4081/monaldi.2022.2062","DOIUrl":null,"url":null,"abstract":"<p><p>The COVID-19 pandemic has led to mortality and morbidity since December 2019. Many possible treatment options have been advised till date. The role of ivermectin in the treatment of COVID-19 disease remains controversial. The aim of our study was to evaluate the effect of ivermectin in hospitalized patients with non-severe and severe COVID-19 disease. We conducted a retrospective cohort study that compared outcomes in 2 groups of COVID-19 patients hospitalized at the largest tertiary care center of Pakistan. The study group was given ivermectin along with standard treatment of covid-19 disease; the comparison group was not. Data on mortality, inflammatory markers such as C-reactive protein (CRP) and ferritin, length of hospital stay and baseline characteristics were collected from Aga Khan University's database from October 2020 till February 2021. Statistical analysis was done to determine the effectiveness of ivermectin in non-severe and severe COVID-19. Comparison of effectiveness of Ivermectin in both the genders was also conducted. The cohort included 188 patients out of which 90 were treated with ivermectin. Mortality and length of hospitalization was not found to be significantly different in the study group compared with the control group (5.6% vs 5.1%; p=0.87 and 5 days vs 4 days; p=0.27). Analysis of secondary outcomes did not yield statistically significant results, apart from ferritin levels which were significantly less in patients treated with ivermectin (547.1 vs 756.7; p=0.03). The ferritin and CRP levels in affected males were higher than in females on admission and discharge. Our findings suggest ivermectin does not significantly affect all-cause mortality, length of hospitalization and CRP levels in hospitalized COVID-19 patients. Large scale randomized controlled trials (RCTs) are required to further evaluate the role of ivermectin in covid-19 disease.</p>","PeriodicalId":520711,"journal":{"name":"Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/monaldi.2022.2062","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

The COVID-19 pandemic has led to mortality and morbidity since December 2019. Many possible treatment options have been advised till date. The role of ivermectin in the treatment of COVID-19 disease remains controversial. The aim of our study was to evaluate the effect of ivermectin in hospitalized patients with non-severe and severe COVID-19 disease. We conducted a retrospective cohort study that compared outcomes in 2 groups of COVID-19 patients hospitalized at the largest tertiary care center of Pakistan. The study group was given ivermectin along with standard treatment of covid-19 disease; the comparison group was not. Data on mortality, inflammatory markers such as C-reactive protein (CRP) and ferritin, length of hospital stay and baseline characteristics were collected from Aga Khan University's database from October 2020 till February 2021. Statistical analysis was done to determine the effectiveness of ivermectin in non-severe and severe COVID-19. Comparison of effectiveness of Ivermectin in both the genders was also conducted. The cohort included 188 patients out of which 90 were treated with ivermectin. Mortality and length of hospitalization was not found to be significantly different in the study group compared with the control group (5.6% vs 5.1%; p=0.87 and 5 days vs 4 days; p=0.27). Analysis of secondary outcomes did not yield statistically significant results, apart from ferritin levels which were significantly less in patients treated with ivermectin (547.1 vs 756.7; p=0.03). The ferritin and CRP levels in affected males were higher than in females on admission and discharge. Our findings suggest ivermectin does not significantly affect all-cause mortality, length of hospitalization and CRP levels in hospitalized COVID-19 patients. Large scale randomized controlled trials (RCTs) are required to further evaluate the role of ivermectin in covid-19 disease.

伊维菌素治疗COVID-19非重症和重症的疗效及性别差异
自2019年12月以来,COVID-19大流行已导致死亡和发病。迄今为止,已经建议了许多可能的治疗方案。伊维菌素在治疗COVID-19疾病中的作用仍存在争议。本研究的目的是评价伊维菌素在非重症和重症COVID-19住院患者中的应用效果。我们进行了一项回顾性队列研究,比较了在巴基斯坦最大的三级医疗中心住院的两组COVID-19患者的结局。研究组患者在治疗covid-19疾病的同时给予伊维菌素;而对照组则不然。从2020年10月至2021年2月,从阿迦汗大学的数据库中收集了死亡率、c反应蛋白(CRP)和铁蛋白等炎症标志物、住院时间和基线特征的数据。统计分析伊维菌素治疗非重症和重症COVID-19的疗效。比较了伊维菌素在两性中的疗效。该队列包括188例患者,其中90例接受伊维菌素治疗。与对照组相比,研究组的死亡率和住院时间无显著差异(5.6% vs 5.1%;P =0.87, 5天vs 4天;p = 0.27)。除了铁蛋白水平在接受伊维菌素治疗的患者中显著降低(547.1 vs 756.7;p = 0.03)。男性患者在入院和出院时铁蛋白和CRP水平均高于女性患者。我们的研究结果表明,伊维菌素对COVID-19住院患者的全因死亡率、住院时间和CRP水平没有显著影响。需要大规模随机对照试验(rct)来进一步评估伊维菌素在covid-19疾病中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信